**NYSTATIN- nystatin suspension**
**McKesson Corporation dba SKY Packaging**

---

**Nystatin Oral Suspension USP**
**[100,000 units per mL]**

**Rx Only**

## DESCRIPTION

Nystatin is an antimycotic polyene antibiotic obtained from *Streptomyces noursei*.

Structural Formula:



Nystatin Oral Suspension USP, for oral administration, contains 100,000 USP Nystatin Units per mL. Inactive ingredients: alcohol (≤ 1% v/v), artificial peppermint flavor, cherry flavor, citric acid, D&C Yellow No. 10, FD&C Red No. 40, glycerin, magnesium aluminum silicate, methylparaben, potassium phosphate dibasic, propylene glycol, propylparaben, purified water and sucrose.

## CLINICAL PHARMACOLOGY

### Pharmacokinetics

Gastrointestinal absorption of nystatin is insignificant. Most orally administered nystatin is passed unchanged in the stool. In patients with renal insufficiency receiving oral therapy with conventional dosage forms, significant plasma concentrations of nystatin may occasionally occur.

### Microbiology

Nystatin is both fungistatic and fungicidal *in vitro* against a wide variety of yeasts and yeast-like fungi. *Candida albicans* demonstrates no significant resistance to nystatin *in vitro* on repeated subculture in increasing levels of nystatin; other *Candida* species

become quite resistant. Generally, resistance does not develop *in vivo*. Nystatin acts by binding to sterols in the cell membrane of susceptible *Candida* species with a resultant change in membrane permeability allowing leakage of intracellular components. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.

## INDICATIONS AND USAGE

Nystatin Oral Suspension is indicated for the treatment of candidiasis in the oral cavity.

## CONTRAINDICATIONS

The preparation is contraindicated in patients with a history of hypersensitivity to any of its components.

## PRECAUTIONS

### General

This medication is not to be used for the treatment of systemic mycoses. Discontinue treatment if sensitization or irritation is reported during use.

### Carcinogenesis, Mutagenesis, Impairment of Fertility

No long-term animal studies have been performed to evaluate carcinogenic potential. There also have been no studies to determine mutagenicity or whether this medication affects fertility in males or females.

### Pregnancy

Teratogenic Effects

Animal reproduction studies have not been conducted with nystatin oral suspension. It is also not known whether nystatin oral suspension can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Nystatin oral suspension should be given to a pregnant woman only if clearly needed.

### Nursing Mothers

It is not known whether nystatin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when nystatin is administered to a nursing woman.

### Pediatric Use

See **DOSAGE AND ADMINISTRATION**.

## ADVERSE REACTIONS

Nystatin is well tolerated even with prolonged therapy. Oral irritation and sensitization have been reported. (See **PRECAUTIONS: General**).

*Gastrointestinal:* Diarrhea (including one case of bloody diarrhea), nausea, vomiting, gastrointestinal upset/disturbances.

*Dermatologic:* Rash, including urticaria has been reported rarely. Stevens-Johnson syndrome has been reported very rarely.

*Other:* Tachycardia, bronchospasm, facial swelling, and non-specific myalgia have also been rarely reported.

**To report SUSPECTED ADVERSE REACTIONS, contact Pharmaceutical Associates, Inc. at 1-800-845-8210 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.**

## OVERDOSAGE

Oral doses of nystatin in excess of five million units daily have caused nausea and gastrointestinal upset. There have been no reports of serious toxic effects of superinfections (See **CLINICAL PHARMACOLOGY, Pharmacokinetics**).

## DOSAGE AND ADMINISTRATION

INFANTS: 2 mL (200,000 units) four times daily (in infants and young children, use dropper to place one-half of dose in each side of mouth and avoid feeding for 5 to 10 minutes).

NOTE: Limited clinical studies in premature and low birth weight infants indicate that 1 mL four times daily is effective.

CHILDREN AND ADULTS: 4 to 6 mL (400,000 to 600,000 units) four times daily (one-half of dose in each side of mouth). The preparation should be retained in the mouth as long as possible before swallowing.

Continue treatment for at least 48 hours after perioral symptoms have disappeared and cultures demonstrate eradication of *Candida albicans*.

## HOW SUPPLIED

Nystatin Oral Suspension USP, 100,000 USP Nystatin Units per mL, is available in a cherry, peppermint flavored, light creamy yellow, ready-to-use suspension, supplied in the following oral dosage forms:

NDC 63739-160-70: 5mL unit dose cup.
NDC 63739-160-56: Case of 50, 5 mL Unit Dose Cups.
NDC 63739-160-10: Case of 100, 5 mL Unit Dose Cups

### Storage

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Avoid freezing.

### Distributed By:

McKesson Corporation
dba SKY Packaging
Memphis, TN 38141

**Manufactured By:**

**Pharmaceutical Associates, Inc**
**www.paipharma.com**

**I0868C0923 Iss09/2023**

**PRINCIPAL DISPLAY PANEL - 5 mL Unit Dose Cup Label**

Delivers **5 mL**

**NDC 63739-160-70**

***NYSTATIN ORAL SUSPENSION, USP***

**500,000 units/5 mL**

Alcohol ≤ 1% v/v **SHAKE WELL**

**Package Not Child-Resistant**

**Rx ONLY**

**SEE INSERT**




# NYSTATIN

nystatin suspension

| Product Information | | | |
|---|---|---|---|
| **Product Type** | HUMAN PRESCRIPTION DRUG | **Item Code (Source)** | NDC:63739-160 |
| **Route of Administration** | ORAL | | |

| Active Ingredient/Active Moiety | | |
|---|---|---|
| **Ingredient Name** | **Basis of Strength** | **Strength** |
| **NYSTATIN** (UNII: BDF1O1C72E) (NYSTATIN - UNII:BDF1O1C72E) | NYSTATIN | 100000 [USP'U] in 1 mL |

| Inactive Ingredients | |
|---|---|
| **Ingredient Name** | **Strength** |
| **ALCOHOL** (UNII: 3K9958V90M) | |
| **ANHYDROUS CITRIC ACID** (UNII: XF417D3PSL) | |
| **D&C YELLOW NO. 10** (UNII: 35SW5USQ3G) | |
| **FD&C RED NO. 40** (UNII: WZB9127XOA) | |
| **GLYCERIN** (UNII: PDC6A3C0OX) | |
| **METHYLPARABEN** (UNII: A2I8C7HI9T) | |
| **POTASSIUM PHOSPHATE, DIBASIC** (UNII: CI71S98N1Z) | |
| **PROPYLENE GLYCOL** (UNII: 6DC9Q167V3) | |

| | |
|---|---|
| **PROPYLPARABEN** (UNII: Z8IX2SC1OH) | |
| **WATER** (UNII: 059QF0KO0R) | |
| **SUCROSE** (UNII: C151H8M554) | |
| **MAGNESIUM ALUMINUM SILICATE** (UNII: 6M3P64V0NC) | |

## Product Characteristics

| | | | |
|---|---|---|---|
| **Color** | | **Score** | |
| **Shape** | | **Size** | |
| **Flavor** | CHERRY, PEPPERMINT | **Imprint Code** | |
| **Contains** | | | |

## Packaging

| # | Item Code | Package Description | Marketing Start Date | Marketing End Date |
|---|---|---|---|---|
| **1** | NDC:63739-160-70 | 5 mL in 1 CUP, UNIT-DOSE; Type 0: Not a Combination Product | 01/29/2024 | 04/30/2026 |
| **2** | NDC:63739-160-10 | 10 in 1 CASE | 01/29/2024 | 04/30/2026 |
| **2** | | 10 in 1 TRAY | | |
| **2** | | 5 mL in 1 CUP, UNIT-DOSE; Type 0: Not a Combination Product | | |
| **3** | NDC:63739-160-56 | 5 in 1 CASE | 01/29/2024 | 04/30/2026 |
| **3** | | 10 in 1 TRAY | | |
| **3** | NDC:63739-160-70 | 5 mL in 1 CUP, UNIT-DOSE; Type 0: Not a Combination Product | | |

## Marketing Information

| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
|---|---|---|---|
| ANDA | ANDA203621 | 01/29/2024 | 04/30/2026 |

## Labeler - McKesson Corporation dba SKY Packaging (140529962)

Revised: 2/2026 McKesson Corporation dba SKY Packaging